[ad_1]
NEW YORK, June 10, 2023 (GLOBE NEWSWIRE) — Paratek Pharmaceuticals, Inc. PRTK
Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of PRTK to Gurnet Point Capital and Novo Holdings A/S for $2.15 per share in cash, plus a CVR of $0.85 per share payable upon the achievement of $320 million in U.S. NUZYRA net sales.
If you are a PRTK investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@lifshitzlaw.com.
CIRCOR International, Inc. CIR
Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of CIR to investment funds managed by KKR for $49.00 per share in cash.
If you are a CIR investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@lifshitzlaw.com.
Reunion Neuroscience, Inc. REUN
Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of REUN to affiliates of MPM BioImpact for $1.12 per share in cash.
If you are a REUN investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@lifshitzlaw.com.
Fate Therapeutics, Inc. FATE
Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Company made materially false and/or misleading statements and/or failed to disclose that: (i) the Janssen Collaboration Agreement was less sustainable than Fate had represented to investors; (ii) accordingly, certain of the clinical programs, milestone payments, and royalty payments associated with the…
[ad_2]
